Literature DB >> 21947660

Association between antimicrobial consumption and clinical isolates of methicillin-resistant Staphylococcus aureus: a 14-year study.

Ayako Nakamura1, Kazunori Miyake, Shigeki Misawa, Yutaka Kuno, Takashi Horii, Satoshi Hori, Shigemi Kondo, Yoko Tabe, Akimichi Ohsaka.   

Abstract

The objective of this study was to determine the relationship between clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) and antimicrobial consumption in hospitalized patients over a 14-year period. The study was retrospectively conducted between January 1995 and December 2008 at Juntendo University Hospital, Tokyo, Japan, a 1,020-bed tertiary-care teaching hospital. The incidence of MRSA isolates was examined using clinical specimens presented to the microbiology laboratory in the hospital. Antimicrobial consumption through intravenous injection was calculated in terms of the number of defined daily doses per 100 bed-days. The correlation between the incidence of MRSA isolates and antimicrobial consumption was determined employing a multiple stepwise regression analysis. A total of 109,946 bacterial isolates were consecutively collected over the 14-year period, and, of these, 13,872 (64% of S. aureus strains excluding coagulase-negative staphylococci) were MRSA strains. The longitudinal observation showed that the number and rate of MRSA isolates marginally decreased. The rate of MRSA isolates among S. aureus strains in 1995 was 68.5%, whereas that in 2008 was 53.8%. Consumption of cephalosporins decreased. Among carbapenems, the rate of imipenem (IPM) consumption decreased, whereas that of meropenem increased. A multiple stepwise regression analysis revealed that the antimicrobial consumption of cefmetazole, cefotiam, and IPM was positively correlated with the incidence of MRSA isolates. The use of β-lactam antimicrobials may contribute to the development of MRSA strains.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21947660     DOI: 10.1007/s10156-011-0302-6

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  6 in total

1.  Microbial spectrum and antibiotic sensitivity in infantile dacryocystitis.

Authors:  Huiling Qing; Zhengwei Yang; Menghai Shi; Junge Zhang; Shengtao Sun; Lei Han
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-01-08       Impact factor: 3.117

Review 2.  MRSA virulence and spread.

Authors:  Michael Otto
Journal:  Cell Microbiol       Date:  2012-07-17       Impact factor: 3.715

3.  Multiple B-cell epitope vaccine induces a Staphylococcus enterotoxin B-specific IgG1 protective response against MRSA infection.

Authors:  Zhuo Zhao; He-Qiang Sun; Shan-Shan Wei; Bin Li; Qiang Feng; Jiang Zhu; Hao Zeng; Quan-Ming Zou; Chao Wu
Journal:  Sci Rep       Date:  2015-07-23       Impact factor: 4.379

4.  The trend of resistance to antibiotics for ocular infection of Staphylococcus aureus, coagulase-negative staphylococci, and Corynebacterium compared with 10-years previous: A retrospective observational study.

Authors:  Hideto Deguchi; Koji Kitazawa; Kanae Kayukawa; Eri Kondoh; Akiko Fukumoto; Toshihide Yamasaki; Shigeru Kinoshita; Chie Sotozono
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

5.  Fine-mapping of immunodominant linear B-cell epitopes of the Staphylococcus aureus SEB antigen using short overlapping peptides.

Authors:  Zhuo Zhao; Bin Li; He-Qiang Sun; Jin-Yong Zhang; Yi-Lin Wang; Li Chen; Jian Hu; Ya-Fei He; Hao Zeng; Quan-Ming Zou; Chao Wu
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

6.  Methicillin Resistant Staphylococcus aureus Transmission in a Ghanaian Burn Unit: The Importance of Active Surveillance in Resource-Limited Settings.

Authors:  Nana Ama Amissah; Andrew H Buultjens; Anthony Ablordey; Lieke van Dam; Ampomah Opoku-Ware; Sarah L Baines; Dieter Bulach; Caitlin S Tetteh; Isaac Prah; Tjip S van der Werf; Alexander W Friedrich; Torsten Seemann; Jan Maarten van Dijl; Ymkje Stienstra; Timothy P Stinear; John W Rossen
Journal:  Front Microbiol       Date:  2017-10-06       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.